{"id":5155,"date":"2019-05-30T16:53:54","date_gmt":"2019-05-30T11:23:54","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=5155"},"modified":"2021-07-24T12:57:21","modified_gmt":"2021-07-24T07:27:21","slug":"the-business-cocktail-cancer-therapies","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-cancer-therapies","title":{"rendered":"The Business Cocktail"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d5fa0cbe383\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d5fa0cbe383\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-cancer-therapies\/#Iovance_infuses_USD_75_M_to_boost_Cancer_therapy\" >Iovance infuses USD 75 M to boost Cancer therapy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-cancer-therapies\/#Novartis_pumps_USD_30_M_into_Ayala_Pharmaceuticals\" >Novartis pumps USD 30 M into Ayala Pharmaceuticals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-cancer-therapies\/#Bayer_and_Foundation_Medicine_collaborate_for_Vitrakvi_diagnostic_development\" >Bayer and Foundation Medicine collaborate for Vitrakvi diagnostic development<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-cancer-therapies\/#Amicus_expands_gene_therapy_collaboration_with_UPenn\" >Amicus expands gene therapy collaboration with UPenn<\/a><\/li><\/ul><\/nav><\/div>\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Iovance_infuses_USD_75_M_to_boost_Cancer_therapy\"><\/span><strong>Iovance infuses USD 75 M to boost Cancer therapy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Iovance Biotherapeutics<\/strong> is all set to build a 136,000-square-foot facility in Philadelphia to develop <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/medullary-thyroid-cancer-market\">cancer <\/a><\/strong>therapies using its <strong>tumour-infiltrating lymphocyte<\/strong> (TIL) technology. Building the new facility will cost the Iovance around <strong>USD 75 Million<\/strong>. The biotherapeutic company is looking to reduce its reliance on contract manufacturing organizations while climbing higher in the market with its leading cancer immunotherapy, lifileucel. The tumour-infiltrating lymphocyte facility will benefit several thousand patients a year.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Novartis_pumps_USD_30_M_into_Ayala_Pharmaceuticals\"><\/span><strong>Novartis pumps USD 30 M into Ayala Pharmaceuticals  <\/strong><br><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>Israel-based <strong>Ayala Pharmaceuticals<\/strong> has successful raised <strong>USD 30 Million<\/strong> in Series B Financing. The investment, coupled with the continued support by Novartis, has been accelerating Ayala\u2019s ability to step up its clinical trial activities. The funds will be used to expedite the mid-phase development of pan-Notch inhibitor <strong>AL101,<\/strong> which recently has been designated an <strong>Orphan Drug Designation<\/strong> by the <strong>FDA <\/strong>in <a href=\"https:\/\/www.delveinsight.com\/report-store\/adenoid-cystic-carcinom-market\"><strong>adenoid cystic carcinoma <\/strong>(<\/a>ACC).<br><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bayer_and_Foundation_Medicine_collaborate_for_Vitrakvi_diagnostic_development\"><\/span><strong>Bayer and Foundation Medicine collaborate for Vitrakvi diagnostic development<\/strong><br><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Bayer <\/strong>has teamed up with the <strong>Foundation Medicine<\/strong> to develop new companion genetic diagnostic tests for several of its <strong>cancer <\/strong>therapies. The initial focus will be on tissue-agnostic <strong>Vitrakvi<\/strong>, which has been granted accelerated approval and is the first targeted cancer drug developed and approved for a pan-cancer indication, in<a href=\"https:\/\/www.delveinsight.com\/report-store\/neuroblastoma-market\"> solid tumours<\/a> with <strong>TRK fusion mutations.<\/strong><br><\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Amicus_expands_gene_therapy_collaboration_with_UPenn\"><\/span><strong>Amicus expands gene therapy collaboration with UPenn <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Amicus Therapeutics<\/strong> has collaborated with the <strong>University of Pennsylvania <\/strong>to increase its presence in inherited metabolic disorders treatment market. <strong>Galafold<\/strong>, one of the Amicus\u2019s marketed products, treats <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/fabry-disease-market\">Fabry disease<\/a><\/strong>&#8211; one such disorder. The partnership is aimed at augmenting the research and development of gene therapies for <strong>lysosomal disorders<\/strong> in which genetically driven enzyme deficiencies lead to a buildup of toxic materials in tissues and 12 additional rare diseases.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Iovance infuses USD 75 M to boost Cancer therapy Iovance Biotherapeutics is all set to build a 136,000-square-foot facility in Philadelphia to develop cancer therapies using its tumour-infiltrating lymphocyte (TIL) technology. Building the new facility will cost the Iovance around USD 75 Million. The biotherapeutic company is looking to reduce its reliance on contract manufacturing [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5118,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[423],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-5155","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-novartis","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>The Business Cocktail 30\/05\/2019 - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"\ufeffIovance Biotherapeutics is all set to build a 136,000-square-foot facility in Philadelphia to develop cancer therapies using tumour-infiltrating-TIL...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-cancer-therapies\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Business Cocktail 30\/05\/2019 - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"\ufeffIovance Biotherapeutics is all set to build a 136,000-square-foot facility in Philadelphia to develop cancer therapies using tumour-infiltrating-TIL...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-cancer-therapies\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-05-30T11:23:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may.png\" \/>\n\t<meta property=\"og:image:width\" content=\"647\" \/>\n\t<meta property=\"og:image:height\" content=\"345\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"The Business Cocktail 30\/05\/2019 - DelveInsight Business Research","description":"\ufeffIovance Biotherapeutics is all set to build a 136,000-square-foot facility in Philadelphia to develop cancer therapies using tumour-infiltrating-TIL...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-cancer-therapies","og_locale":"en_US","og_type":"article","og_title":"The Business Cocktail 30\/05\/2019 - DelveInsight Business Research","og_description":"\ufeffIovance Biotherapeutics is all set to build a 136,000-square-foot facility in Philadelphia to develop cancer therapies using tumour-infiltrating-TIL...","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-cancer-therapies","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-05-30T11:23:54+00:00","article_modified_time":"2021-07-24T07:27:21+00:00","og_image":[{"width":647,"height":345,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-cancer-therapies","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-cancer-therapies","name":"The Business Cocktail 30\/05\/2019 - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-cancer-therapies#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-cancer-therapies#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may.png","datePublished":"2019-05-30T11:23:54+00:00","dateModified":"2021-07-24T07:27:21+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"\ufeffIovance Biotherapeutics is all set to build a 136,000-square-foot facility in Philadelphia to develop cancer therapies using tumour-infiltrating-TIL...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-cancer-therapies"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-cancer-therapies#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may.png","width":647,"height":345,"caption":"Business cocktail"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may-300x160.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novartis<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Novartis<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on May 30, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on May 30, 2019 4:53 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Business cocktail","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5155","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=5155"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5155\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/5118"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=5155"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=5155"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=5155"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=5155"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=5155"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}